Global Cord Blood Corporation (CO): Price and Financial Metrics
GET POWR RATINGS... FREE!
CO Stock Price Chart Interactive Chart >
CO Price/Volume Stats
| Current price | $2.69 | 52-week high | $6.31 |
| Prev. close | $2.64 | 52-week low | $2.10 |
| Day low | $2.65 | Volume | 91,407 |
| Day high | $2.73 | Avg. volume | 163,296 |
| 50-day MA | $3.53 | Dividend yield | N/A |
| 200-day MA | $4.17 | Market Cap | 326.97M |
Global Cord Blood Corporation (CO) Company Bio
Global Cord Blood Corporation provides umbilical cord blood storage and ancillary services in China. The company is based in Central, Hong Kong.
Latest CO News From Around the Web
Below are the latest news stories about Global Cord Blood Corp that investors may wish to consider to help them evaluate CO as an investment opportunity.
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal 2022, ended December 31, 2021. |
Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial ResultsGlobal Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close. |
Global Cord Blood Corporation Announces Rejection of Alternate Ocean ProposalGlobal Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its Board of Directors (the "Board") decided to reject the non-binding proposal letter ("Alternate Ocean Proposal") from Alternate Ocean Investment Company Limited ("Alternate Ocean") received by the Board dated March 2, 2021, pursuant to which Alternate Ocean proposed to |
Global Cord Blood Corporation Announces Results of 2021 Annual General MeetingGlobal Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021, in Hong Kong S.A.R., China. |
Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2022Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half of fiscal 2022 ended September 30, 2021. |
CO Price Returns
| 1-mo | N/A |
| 3-mo | -38.44% |
| 6-mo | -37.00% |
| 1-year | -48.17% |
| 3-year | -58.42% |
| 5-year | -64.58% |
| YTD | -35.80% |
| 2021 | 12.94% |
| 2020 | -25.80% |
| 2019 | -22.48% |
| 2018 | -34.53% |
| 2017 | 62.58% |
Continue Researching CO
Want to see what other sources are saying about Global Cord Blood Corp's financials and stock price? Try the links below:Global Cord Blood Corp (CO) Stock Price | Nasdaq
Global Cord Blood Corp (CO) Stock Quote, History and News - Yahoo Finance
Global Cord Blood Corp (CO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...